Clinical Trial

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

Study acronym: TALENT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate.
Protocol Amendment History 1 change
notable Trial sites expanded: 2 -> 5 locations 2026-06-16
Trial Details
NCT Number NCT06844383
Lead Sponsor Prostate Cancer Clinical Trials Consortium
Collaborators: Pfizer, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center
Conditions Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Enrollment 126 participants
Start Date 2026-05-05
Primary Completion 2029-03 (estimated)
Study Completion 2030-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-13